AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7785746 — intervention group
Group type: COMPARATOR
Intervention: Nedocromil sodium 2% eye drops (n=155)
Number of subjects: 2905
Study 2204243 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent Salmonella typhi-Shigella sonnei vaccine, 3 doses of 10^9 organisms each
Number of subjects: 18
Study 2204243 — intervention group
Group type: COMPARATOR
Intervention: Previous infection with S. sonnei
Number of subjects: 18
Study 313717 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle training and percutaneous electrical stimulation
Number of subjects: 8
Study 313717 — intervention group
Group type: COMPARATOR
Intervention: Standard plaster cast and isometric muscle training
Number of subjects: 8
Study 31023272 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian green propolis extract at a dose of 500 mg/day for 12 months
Number of subjects: 32
Study 31023272 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 32
Study 27891757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin alone (25 mg once daily)
Number of subjects: 0
Study 27891757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin/metformin once daily (500 mg once daily)
Number of subjects: 0
Study 27891757 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin/metformin twice daily (250 mg twice daily)
Number of subjects: 0
Study 27891757 — intervention group
Group type: COMPARATOR
Intervention: Alogliptin/metformin once daily
Number of subjects: 0
Study 25540059 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg once daily starting 3 days preoperatively and continuing within 5 days postoperatively
Number of subjects: 58
Study 25540059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 22528588 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg/day (600 IU/day) for 8 weeks (Group A)
Number of subjects: 65
Study 22528588 — intervention group
Group type: COMPARATOR
Intervention: Not treated (Group B)
Number of subjects: 65
Study 22528588 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline values (Group A before treatment)
Number of subjects: 65
Study 22147126 — intervention group
Group type: EXPERIMENTAL
Intervention: introducer PEG-gastropexy technique without antibiotics
Number of subjects: 18
Study 22147126 — intervention group
Group type: COMPARATOR
Intervention: pull PEG with antibiotics
Number of subjects: 18
Study 22147126 — intervention group
Group type: EXPERIMENTAL
Intervention: both methods
Number of subjects: 18
Study 19008491 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention (Internet-delivered PA program)
Number of subjects: 41
Study 19008491 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed intent-to-treat)
Number of subjects: 41
Study 19008491 — intervention group
Group type: EXPERIMENTAL
Intervention: ALED-I intervention
Number of subjects: 41
Study 19008491 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 17074945 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated psychological and nicotine replacement therapy intervention (8 sessions)
Number of subjects: 298
Study 17074945 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 298
Study 15636169 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) supplementation (40 g daily for 3 months)
Number of subjects: 135
Study 15636169 — intervention group
Group type: COMPARATOR
Intervention: Milk‐based protein (MP)
Number of subjects: 135
Study 15636169 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) in men
Number of subjects: 135
Study 15636169 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (SP) in women
Number of subjects: 135
Study 11716313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats/milk group
Number of subjects: 127
Study 11716313 — intervention group
Group type: EXPERIMENTAL
Intervention: Oats/soy group
Number of subjects: 127
Study 11716313 — intervention group
Group type: COMPARATOR
Intervention: Wheat/soy group
Number of subjects: 127
Study 11716313 — intervention group
Group type: COMPARATOR
Intervention: Wheat/milk group
Number of subjects: 127
Study 9152063 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal S antigen alone
Number of subjects: 45
Study 9152063 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal S antigen and a mixture of soluble retinal antigens
Number of subjects: 45
Study 9152063 — intervention group
Group type: EXPERIMENTAL
Intervention: A mixture of soluble retinal antigens alone
Number of subjects: 45
Study 9152063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 7970122 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 3 months (group NL)
Number of subjects: 50
Study 7970122 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg preoperatively and 20 mg b.d. postoperatively for 48 h followed by placebo for 3 months (group NS)
Number of subjects: 50
Study 7970122 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 50
Study 2119152 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 29
Study 2119152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 364631 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium bromide (100 mg in 100 ml saline solution)
Number of subjects: 20
Study 364631 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (100 ml)
Number of subjects: 20
Study 31818694 — intervention group
Group type: EXPERIMENTAL
Intervention: bioceramics wrap
Number of subjects: 24
Study 31818694 — intervention group
Group type: COMPARATOR
Intervention: placebo wrap
Number of subjects: 24
Study 31481549 — intervention group
Group type: EXPERIMENTAL
Intervention: PDD-guided TURBT
Number of subjects: 0
Study 31481549 — intervention group
Group type: COMPARATOR
Intervention: Standard white light resection
Number of subjects: 0
Study 27860410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 150 mg every 2 weeks
Number of subjects: 0
Study 27860410 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 mg every 2 weeks
Number of subjects: 0
Study 27860410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25459913 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 39
Study 25459913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23464532 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 10-140 mg
Number of subjects: 458
Study 23464532 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 20-200 mg
Number of subjects: 458
Study 23464532 — intervention group
Group type: COMPARATOR
Intervention: Glipizide 5-20 mg
Number of subjects: 458
Study 23464532 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label AZD1656 20-200 mg
Number of subjects: 458
Study 23464532 — intervention group
Group type: COMPARATOR
Intervention: AZD1656 (extension population)
Number of subjects: 458
Study 21694588 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTBAu (bone-patellar tendon-bone autograft)
Number of subjects: 0
Study 21694588 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTBAll (BPTB allograft)
Number of subjects: 0
Study 21694588 — intervention group
Group type: EXPERIMENTAL
Intervention: HTAu (hamstring tendon autograft)
Number of subjects: 0
Study 21694588 — intervention group
Group type: COMPARATOR
Intervention: All groups (BPTBAu, BPTBAll, HTAu)
Number of subjects: 0
Study 19041436 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 mcg + CMA 2 mg (Belara)
Number of subjects: 45
Study 19041436 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 30 mcg + Desogestrel 0.15 mg (Marvelon)
Number of subjects: 45
Study 16954556 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-DTPA-D-Phe1-octreotide therapy
Number of subjects: 12
Study 16954556 — intervention group
Group type: EXPERIMENTAL
Intervention: Transhepatic administration of 111In-DTPA-D-Phe1-octreotide
Number of subjects: 12
Study 15142997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hatching blastocyst stage ET (Hat ET; n = 240)
Number of subjects: 480
Study 15142997 — intervention group
Group type: COMPARATOR
Intervention: Day 3 ET (n = 240)
Number of subjects: 480
Study 11318056 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronization-Continuation Task with ITI from 0.4 s to 2.2 s
Number of subjects: 0
Study 9159033 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 1b
Number of subjects: 217
Study 9159033 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV genotype 2a
Number of subjects: 217
Study 9159033 — intervention group
Group type: COMPARATOR
Intervention: HCV genotypes distribution
Number of subjects: 217
Study 7684579 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW‐HES (high‐molecular weight hydroxyethyl starch solution)
Number of subjects: 60
Study 7684579 — intervention group
Group type: EXPERIMENTAL
Intervention: LMW‐HES (low‐molecular weight hydroxyethyl starch)
Number of subjects: 60
Study 7684579 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5% gelatin
Number of subjects: 60
Study 7684579 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 60
Study 7684579 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (15 patients)
Number of subjects: 60
Study 7684579 — intervention group
Group type: EXPERIMENTAL
Intervention: HMW‐HES
Number of subjects: 60
Study 3107331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal thiopentone 30 mg X kg‐1
Number of subjects: 72
Study 3107331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 20 mg X kg‐1
Number of subjects: 72
Study 3107331 — intervention group
Group type: EXPERIMENTAL
Intervention: Methohexitone 30 mg X kg‐1
Number of subjects: 72
Study 3107331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 72
Study 30608593 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Contact (DC)
Number of subjects: 1812
Study 30608593 — intervention group
Group type: COMPARATOR
Intervention: Hospital Episode Statistics (HES)
Number of subjects: 1812
Study 27240681 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to 'be your own advocate'
Number of subjects: 59
Study 27240681 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to 'have someone you can rely on'
Number of subjects: 59
Study 27240681 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to 'think positive'
Number of subjects: 59
Study 27748565 — intervention group
Group type: EXPERIMENTAL
Intervention: GOT + IOT (n=30)
Number of subjects: 51
Study 27748565 — intervention group
Group type: COMPARATOR
Intervention: GOT alone (n=21)
Number of subjects: 51
Study 24085535 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 126
Study 24085535 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 126
Study 23957447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen
Number of subjects: 305
Study 23957447 — intervention group
Group type: COMPARATOR
Intervention: Air (atmospheric air)
Number of subjects: 305
Study 20438223 — intervention group
Group type: EXPERIMENTAL
Intervention: High construal level negotiation
Number of subjects: 0
Study 20438223 — intervention group
Group type: EXPERIMENTAL
Intervention: Low construal level negotiation
Number of subjects: 0
Study 18199695 — intervention group
Group type: EXPERIMENTAL
Intervention: Control over food choice and access to healthy/unhealthy food options
Number of subjects: 16
Study 18199695 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for unhealthy food items
Number of subjects: 16
Study 18199695 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to educate food providers
Number of subjects: 16
Study 16277628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangover group (n = 38)
Number of subjects: 71
Study 16277628 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 33)
Number of subjects: 71
Study 12505553 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Management Training (AMT) for 9 weeks
Number of subjects: 20
Study 12505553 — intervention group
Group type: COMPARATOR
Intervention: Progressive Relaxation (PR) for 9 weeks
Number of subjects: 20
Study 10473234 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinupristin/dalfopristin
Number of subjects: 893
Study 10473234 — intervention group
Group type: COMPARATOR
Intervention: Comparator (cefazolin, oxacillin, or vancomycin)
Number of subjects: 893
Study 8661629 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle-sparing thoracotomy (MS group, n = 15)
Number of subjects: 30
Study 8661629 — intervention group
Group type: COMPARATOR
Intervention: Standard thoracotomy (SP group, n = 15)
Number of subjects: 30
Study 2050997 — intervention group
Group type: EXPERIMENTAL
Intervention: 55 s.c. injection course of 5 M unit recombinant human alpha‐interferon (group 1, 14 patients)
Number of subjects: 29
Study 2050997 — intervention group
Group type: COMPARATOR
Intervention: Adenine‐arabinoside (for 21 days) combined from the fourteenth day on with the same 55 s.c. injection schedule of interferon (group 2, 15 cases)
Number of subjects: 29
Study 2050997 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 6407408 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C, 20 mg/m2 I.V. direct once every 6 weeks, four courses
Number of subjects: 70
Study 6407408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 31049052 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually adjusted alpha/delta neurofeedback protocol
Number of subjects: 26
Study 29949233 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the health belief model
Number of subjects: 135
Study 29949233 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 28480365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at LR3
Number of subjects: 45
Study 28480365 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 45
Study 28480365 — intervention group
Group type: COMPARATOR
Intervention: Sham acupoint
Number of subjects: 45
Study 24585160 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattress system with low-air-loss technology
Number of subjects: 20
Study 24585160 — intervention group
Group type: EXPERIMENTAL
Intervention: Backrest elevation at 45°
Number of subjects: 20
Study 24585160 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse Trendelenburg position
Number of subjects: 20
Study 22739368 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet (fermentable carbohydrate restriction)
Number of subjects: 35
Study 22739368 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (control)
Number of subjects: 35
Study 19567493 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg
Number of subjects: 117
Study 19567493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17631795 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation treatment
Number of subjects: 70
Study 17631795 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 70
Study 15200444 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hemodialysis
Number of subjects: 0
Study 15200444 — intervention group
Group type: COMPARATOR
Intervention: High flux membranes
Number of subjects: 0
Study 12759208 — intervention group
Group type: COMPARATOR
Intervention: Conventional vein harvest and storage in a crystalloid solution
Number of subjects: 80
Study 12759208 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic vein harvest and storage in crystalloid solution
Number of subjects: 80
Study 12759208 — intervention group
Group type: COMPARATOR
Intervention: Conventional harvest under continuous perfusion of the vein with 100 ml blood via the heart lung machine
Number of subjects: 80
Study 12759208 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic vein harvest under continuous perfusion
Number of subjects: 80
Study 9422580 — intervention group
Group type: EXPERIMENTAL
Intervention: VacFix bags for immobilization
Number of subjects: 36
Study 9422580 — intervention group
Group type: COMPARATOR
Intervention: No immobilization
Number of subjects: 36
Study 9422580 — intervention group
Group type: EXPERIMENTAL
Intervention: General treatment with increased radiation doses
Number of subjects: 36
Study 9422580 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of portal images for verification
Number of subjects: 36
Study 7866003 — intervention group
Group type: EXPERIMENTAL
Intervention: Valeriana officinalis var latifolia (VOL)
Number of subjects: 82
Study 7866003 — intervention group
Group type: COMPARATOR
Intervention: Salvia miltiorrhiza composite injection (SMCo)
Number of subjects: 82
Study 2502567 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 2% mupirocin ointment, applied three times a day for seven days
Number of subjects: 70
Study 2502567 — intervention group
Group type: COMPARATOR
Intervention: Topical 2% fusidic acid ointment, applied three times a day for seven days
Number of subjects: 70
Study 800382 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (Orudis)
Number of subjects: 23
Study 800382 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 23
Study 31464753 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodynamic mobilization plus motor control exercises
Number of subjects: 32
Study 31464753 — intervention group
Group type: COMPARATOR
Intervention: Motor control exercises alone
Number of subjects: 32
Study 31392892 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV DNA detection
Number of subjects: 1301
Study 31392892 — intervention group
Group type: COMPARATOR
Intervention: Rapid test (RT)
Number of subjects: 1301
Study 27183325 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal Group (RG) - granulomatous tissue was removed
Number of subjects: 60
Study 27183325 — intervention group
Group type: COMPARATOR
Intervention: Left Group (LG) - granulomatous tissue was left
Number of subjects: 60
Study 27183325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RG and LG)
Number of subjects: 60
Study 25886378 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks with Bevacizumab (BEV) 5 mg/kg once every 2 weeks (3 doses)
Number of subjects: 90
Study 25886378 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (CAP) 825 mg/m² twice daily for 5 days per week for 5 weeks without Bevacizumab (BEV)
Number of subjects: 90
Study 22968823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection (20 mg, 1-3 injections at 3-week intervals)
Number of subjects: 95
Study 22968823 — intervention group
Group type: COMPARATOR
Intervention: Observation-only (control group)
Number of subjects: 95
Study 22968823 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival triamcinolone injection
Number of subjects: 95
Study 21480416 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 5 mg once daily for 3 weeks
Number of subjects: 23
Study 21480416 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 20 mg once daily for 3 weeks
Number of subjects: 23
Study 19358618 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 16 mg/day
Number of subjects: 838
Study 19358618 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 838
Study 19358618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 838
Study 17704979 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron extracts
Number of subjects: 0
Study 15031516 — intervention group
Group type: EXPERIMENTAL
Intervention: Okavax (varicella vaccine)
Number of subjects: 300
Study 15031516 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimovax (MMR vaccine)
Number of subjects: 300
Study 15031516 — intervention group
Group type: EXPERIMENTAL
Intervention: Okavax and Trimovax administered concomitantly
Number of subjects: 300
Study 15031516 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant administration of Okavax and Trimovax
Number of subjects: 300
Study 15031516 — intervention group
Group type: COMPARATOR
Intervention: Trimovax only
Number of subjects: 300
Study 15031516 — intervention group
Group type: COMPARATOR
Intervention: Okavax only
Number of subjects: 300
Study 11340271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine injected before trocar entry (Group 1)
Number of subjects: 45
Study 11340271 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine injected after trocar removal (Group 2)
Number of subjects: 45
Study 11340271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 45
Study 9462438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 3 mg/kg once daily
Number of subjects: 50
Study 9462438 — intervention group
Group type: COMPARATOR
Intervention: Nystatin 50,000 units/kg/day in four divided doses
Number of subjects: 50
Study 9462438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 50
Study 9462438 — intervention group
Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 50
Study 7935145 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier creams
Number of subjects: 868
Study 7935145 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocarbon cream
Number of subjects: 868
Study 3127585 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin (AF) treatment
Number of subjects: 0
Study 3127585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31948853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise and dietary protein intervention
Number of subjects: 168
Study 31948853 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 168
Study 28689511 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM+ intervention (five weekly sessions of 2 hours duration delivered by local non-specialist females under supervision)
Number of subjects: 120
Study 28689511 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (control group)
Number of subjects: 120
Study 29871263 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray combined with oral montelukast
Number of subjects: 138
Study 29871263 — intervention group
Group type: COMPARATOR
Intervention: Mometasone furoate nasal spray alone
Number of subjects: 138